MedPath

DROTAVERINE HYDROCHLORIDE VERSUS HYOSCINE BUTYLBROMIDE IN REDUCING FIRST STAGE OF LABOUR AMONG NULLIPARAE : A RANDOMIZED CONTROLLED TRIA

Not Applicable
Completed
Conditions
Pregnancy and Childbirth
Registration Number
PACTR202206902932545
Lead Sponsor
nenna S Nweke
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
165
Inclusion Criteria

1.Nulliparae
2.Women who consented to participate in the study
3.Women with fetus in cephalic presentation
4.Singleton fetus with no evidence of maternal or fetal distress.
5.Women with no contraindication to vaginal delivery.
6.Term pregnancies with intact or ruptured membranes
7.Cervical dilatation of 4-5 cm only
8.Spontaneous or induced labour
9.Patients on epidural

Exclusion Criteria

1 Women with abnormal fetal presentation.
2. Women in latent phase of labour.
3. Preterm / term premature rupture of membranes.
4. Antepartum haemorrhage.
5. Those who refused to consent.
6. Previous uterine scar or surgery.
7. Huge fibroid in pregnancy.
8. Multiple gestations.
9. Multiparous or grand multiparous patients.
10. Medical diseases in pregnancy such as severe preeclampsia/eclampsia and others.
11. History of cervical surgery.
12. Hypersensitivity to drotaverine hydrochloride.
13. Any contraindication to vaginal delivery

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.